Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience.
METHODS
Capecitabine and temozolomide chemotherapy was used in 65 patients with grade 1/2 neuroendocrine tumors (NETs). 46 patients (70.8%) had pancreatic NETs (pNETs).


RESULTS
Response rate was 47.7%, with two complete responses (3.1%), 29 partial responses (44.6%) and 27 patients (41.5%) achieved stable disease. Median progression-free survival was 16.1 months (95% CI: 10.7-21.6) and overall survival was 38.3 months (95% CI: 24.6-51.9). Differences in progression-free survival and overall survival between pNETs and non-pNETs were not found. Nine (13.8%) patients experienced grade 3/4 toxicities, mainly thrombocytopenia (10.8%) and neutropenia (7.7%).


CONCLUSIONS
This is the largest reported series of NETs treated with capecitabine and temozolomide in daily practice and shows that this combination is a promising treatment option for both grade 1/2 pNETs and non-pNETs.
Department of Medical Oncology, Hospital Universitario de Burgos, Burgos, Spain.
Guillermo
G
Crespo
Department of Medical Oncology, Hospital Universitario Central de Asturias, Oviedo, Spain.
Paula
P
Jiménez-Fonseca
Department of Medical Oncology, Hospital Universitario La Paz, Madrid, Spain.
Ana
A
Custodio
Department of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Carlos
C
López
Department of Medical Oncology, Hospital Universitario Morales Meseguer, Murcia, Spain.
Alberto
A
Carmona-Bayonas
Department of Medical Oncology, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Vicente
V
Alonso
Department of Medical Oncology, Hospital Clínico Universitario de Salamanca, Salamanca, Spain.
Miguel
M
Navarro
Endocrinology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
Javier
J
Aller
Department of Medical Oncology, Hospital Clínico Virgen de la Victoria y Regional de Málaga, Málaga, Spain.
Isabel
I
Sevilla
Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Enrique
E
Grande
Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Pablo
P
Gajate
Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain.
Teresa
T
Alonso-Gordoa
Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
Ignacio
I
Matos
Department of Medical Oncology, Hospital Universitari Vall d'Hebron, Universitat Autónoma de Barcelona, Barcelona, Spain.
Jaume
J
Capdevila
Department of Medical Oncology, Hospital Universitario de León, León, Spain.
Beatriz
B
Nieto
Department of Medical Oncology, University of Manchester, Manchester, UK.
Jorge
J
Barriuso
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000069287:Capecitabine / Q000008:administration & dosage; D003606:Dacarbazine / Q000008:administration & dosage / Q000031:analogs & derivatives; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D060787:Neoplasm Grading; D018358:Neuroendocrine Tumors / Q000175:diagnosis* / Q000188:drug therapy* / Q000401:mortality; D016016:Proportional Hazards Models; D013030:Spain; D016019:Survival Analysis; D000077204:Temozolomide; D016896:Treatment Outcome
D000069287:Capecitabine; D003606:Dacarbazine; D000077204:Temozolomide
capecitabine; carcinoids; neuroendocrine tumors; pancreatic neuroendocrine tumors; retrospective study; temozolomide